Recipharm AB Acquires Vibalogics from Ampersand Capital Partners

Ampersand Capital Partners Makes Growth Investment in Vibalogics GmbH

May 29, 2019

Biotechnology

Ampersand Capital Partners has made a growth equity investment in Vibalogics GmbH, a German CDMO specializing in development and GMP manufacturing of complex viral products. The investment will fund expansion of Vibalogics' process development and manufacturing capabilities and support broader growth in the U.S. and European markets.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

Ampersand Capital Partners Acquires Biologos LLC

March 19, 2024

Biotechnology

Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.

PharmaLogic Holdings Corp. Acquires Majority Stake in Agilera Pharma AS

April 10, 2025

Pharmaceuticals

PharmaLogic Holdings Corp. has agreed to acquire a majority stake in Norway-based Agilera Pharma AS from the Institute for Energy Technology (IFE), creating an expanded, integrated global CDMO focused on radiopharmaceutical therapeutics. The deal strengthens PharmaLogic's manufacturing, development, and distribution capabilities for radiopharmaceuticals and is expected to close in June 2025, pending customary approvals.

GHO Capital and Ampersand Acquire Avid Bioservices for $1.1 Billion

November 7, 2024

Biotechnology

GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, a dedicated biologics CDMO, in an all-cash transaction valued at approximately $1.1 billion. The transaction takes Avid private (shareholders received $12.50 per share) and positions the company for capability expansion, geographic reach and accelerated growth under the new PE ownership.

Recipharm Acquires Arranta Bio

February 18, 2022

Biotechnology

Recipharm has acquired Arranta Bio, a US-based CDMO specializing in advanced therapy medicinal products (ATMPs), microbiome therapeutics and mRNA manufacturing, to expand its biologics and ATMP capabilities and establish a stronger US presence. Arranta Bio brings fermentation, purification, analytics and end-to-end mRNA drug substance and drug product capabilities; the transaction was expected to close around the end of March 2022.